This article was originally published in The Gray Sheet
Inks agreement to sell $15 mil. in convertible zero coupon debentures to investment funds managed by Brown Simpson Asset Management, LLC and Rose Glen Capital Management, L.P., bringing total cash available to $56 mil. The securities are convertible at $10 per share at the company's option "when the common stock has traded at a certain premium to the fixed conversion price for five (5) consecutive trading days." The Menlo Park, California-based developer of therapeutic drugs and diagnostic products plans to use the proceeds to accelerate programs related to "recent discoveries in embryonic stem cell technology as well as our telomerase programs"
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.